NK Ibrahim

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer

Ana M. González-Angulo, Argun Akçakanat, S. Liu et al. · Annals of Oncology · 2014 · 104 citations · Full text

Medicine, Oncology, Pharmacology +13

Enhanced Chemoresistance by Elevation of p185neu Levels in HER-2/neu-Transfected Human Lung Cancer Cells

Chih–Chien Tsai, Dihua Yu, K.-T. Chang et al. · JNCI Journal of the National Cancer Institute · 1995 · 90 citations

Medicine, Cancer Biology, Oncology +9

Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis

Shlomit Yust‐Katz, Pedro Garciarena, D. Liu et al. · Journal of Neuro-Oncology · 2013 · 65 citations

Medicine, Endocrinology, Oncology +11

Open label, randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) versus the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC).

Ana M. González-Angulo, M. C. Green, James L. Murray et al. · Journal of Clinical Oncology · 2011 · 29 citations

Medicine, Oncology, Pharmacology +17

Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine

NK Ibrahim, James L. Murray, Jennifer J. Parker et al. · Journal of Clinical Oncology · 2004 · 17 citations

Medicine, Immunology, Oncology +17